Jazz Pharmaceuticals plc (JAZZ)

IE — Healthcare Sector
Peers: INCY  ALNY  UTHR  RARE  APLS  BMRN  SGEN  EXEL  HALO  PCVX  LQDA  LEGN  TECH  INBX  PTGX  DICE  LRMR  VRDN  BPMC  ASND  ARGX  DNLI 

Automate Your Wheel Strategy on JAZZ

With Tiblio's Option Bot, you can configure your own wheel strategy including JAZZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol JAZZ
  • Rev/Share 66.6591
  • Book/Share 68.4644
  • PB 1.5891
  • Debt/Equity 1.2982
  • CurrentRatio 3.3762
  • ROIC 0.0766

 

  • MktCap 6707792000.0
  • FreeCF/Share 24.4087
  • PFCF 4.5067
  • PE 13.7589
  • Debt/Assets 0.4699
  • DivYield 0
  • ROE 0.119

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade JAZZ UBS Neutral Buy $145 $179 March 7, 2025
Downgrade JAZZ Cantor Fitzgerald Overweight Neutral -- -- Feb. 26, 2025
Upgrade JAZZ Wells Fargo Equal Weight Overweight $130 $170 Feb. 13, 2025
Upgrade JAZZ Morgan Stanley Equal Weight Overweight $140 $175 Dec. 12, 2024

News

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
JAZZ
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
JAZZ
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral

Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera® (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC …

Read More
image for news Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Jazz Pharmaceuticals: One Step Forward, One Back
JAZZ
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral

Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection point in 2026.

Read More
image for news Jazz Pharmaceuticals: One Step Forward, One Back
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
JAZZ
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Read More
image for news Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
JAZZ
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.

Read More
image for news JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
JAZZ
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Jessica Fye - JP Morgan David Amsellem - Piper Sandler Marc Goodman - Leerink Partners. Annabel Samimy - Stifle Joseph Thome - TD Cowen Gregory Renza - RBC Capital Markets …

Read More
image for news Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
JAZZ
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
JAZZ
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago.

Read More
image for news Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
JAZZ
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
JAZZ
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.

Read More
image for news Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
3 Unconventional Cannabis Stocks to Watch in 2025
CRBP, JAZZ, PM
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.

Read More
image for news 3 Unconventional Cannabis Stocks to Watch in 2025
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
JAZZ
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral

DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.1 "This positive CHMP opinion is a welcome step for physicians and patients in Europe who …

Read More
image for news Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
HRMY, JAZZ
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.

Read More
image for news JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
ARGX, JAZZ
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Read More
image for news JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
JAZZ
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
JAZZ
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Read More
image for news Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
AES, ANET, GLW, JAZZ, PPC
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.

Read More
image for news 5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
ARGX, JAZZ
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Read More
image for news JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
JAZZ
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
4 Top PEG Stocks Based on GARP Approach to Smart Investing
DAN, FMS, ITRI, JAZZ
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Neutral

Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.

Read More
image for news 4 Top PEG Stocks Based on GARP Approach to Smart Investing
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
JAZZ
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
ILMN, JAZZ
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

Read More
image for news JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
JAZZ
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
BMRN, DVN, JAZZ, TAP
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.

Read More
image for news 4 Discounted PEG Stocks Offering the Best Returns to Value Investors
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
JAZZ, PGR, PSO, TXO
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive

It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.

Read More
image for news Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
JAZZ
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
Best Momentum Stocks to Buy for March 3rd
BATRA, JAZZ, STRL
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive

STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.

Read More
image for news Best Momentum Stocks to Buy for March 3rd
4 Stocks Trading Near 52-Week High With More Upside Potential
ENS, JAZZ, NFG, TAP
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Stocks like NFG, ENS, TAP and JAZZ are seeing price strength and have a high chance of carrying the momentum forward.

Read More
image for news 4 Stocks Trading Near 52-Week High With More Upside Potential
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
JAZZ
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
JAZZ
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.

Read More
image for news Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab

About Jazz Pharmaceuticals plc (JAZZ)

  • IPO Date 2007-06-01
  • Website https://www.jazzpharma.com
  • Industry Biotechnology
  • CEO Mr. Bruce C. Cozadd
  • Employees 2800

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.